AGRX News and Press, Agile Therapeutics Inc. From 02/13/19

On February 11 th , Agile Therapeutics ( AGRX ) reported topline results from their comparative wear study challenging the adhesion of Twirla matched against Xulane (Figure 1). Once the news hit the wire, AGRX quickly traded up above $1.00 in the premarket but was quickly hit with selling ...

Thinly traded nano cap Agile Therapeutics (NASDAQ: AGRX ) is up 22% premarket on increased volume in response to its announcement of successful results from a comparative wear study assessing the adhesion of contraceptive patch Twirla (levonorgestrel/ethinyl estradiol transdermal system)...

Company now focused on completing plan to resubmit NDA in first half of 2019 PRINCETON, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women’s healthcare company, today announced topline results from a comparative wear study testing the adhe...

PRINCETON, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the 2019 BIO CEO & Investor conference on Tuesday February 12, 2019 at 10:...

It has been a rough couple years for Agile Therapeutics (AGRX), and the share price has taken the brunt of it. The company has been struggling for years to get their once-weekly contraceptive patch, Twirla, approved by the FDA. Twirla has received two CRLs from FDA, with the most recent occurr...